We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Roche Expands Digital Pathology Open Environment with Integration of Advanced AI Algorithms from New Collaborators

By LabMedica International staff writers
Posted on 10 Sep 2024

Roche (Basel, Switzerland) has expanded its digital pathology open environment by integrating over 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by employing cutting-edge AI technology.

Roche delivers an end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated AI-based clinical image analysis algorithms. Roche reduces variables that can impact analysis, with this end-to-end development generating quality results healthcare providers and researchers can rely on. Following the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented AI tools into routine clinical practice. The Roche Digital Pathology Open Environment acts as a collaborative platform that integrates innovative AI-based pathology tools.


Image: Roche has expanded its digital pathology open environment with more than 20 AI algorithms (Photo courtesy of Roche)
Image: Roche has expanded its digital pathology open environment with more than 20 AI algorithms (Photo courtesy of Roche)

Roche’s collaborators include:

The seamless integration is facilitated through Roche's navify® Digital Pathology enterprise software, an application for the pathologist's workflow, which now incorporates a wide range of AI-driven algorithms, offering easy access to third-party innovation. These AI tools are designed to improve pathology insights, aiding benefit cancer patients through precision medicine and enabling targeted treatments. These new collaborations and integrations are in line with Roche’s commitment to improving patient outcomes and advancing personalized healthcare by offering scientists and clinicians the resources required to deliver accurate and reliable cancer diagnoses.

"We are excited to welcome these new collaborators into our digital pathology ecosystem," said Jill German, Head of Pathology Lab for Roche Diagnostics. "By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionize cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide."


Gold Member
Turnkey Packaging Solution
HLX
Unit-Dose Packaging solution
HLX
New
Four-in-One Desktop Testing Solution
GULP-1sim/GULP-1ble
New
EBV DNA Quantitative Fluorescence Diagnostic Kit
S3015E EBV

Latest Industry News

Roche to Develop New Diagnostic Technologies for Traumatic Brain Injuries

LGC Clinical Diagnostics and AccuGenomics Collaborate on Enhancing Cancer Testing Accuracy

Beckman Coulter and SphingoTec Partner to Improve Kidney Health Assessment in Critical Care